So Min Wook, Koo Bon San, Kim You Jae, Kim Yong-Gil, Lee Chang-Keun, Yoo Bin
Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center , Seoul , Korea.
Mod Rheumatol. 2014 Sep;24(5):855-7. doi: 10.3109/14397595.2013.874740. Epub 2014 Feb 11.
High-dose steroids, immunosuppressants such as cyclophosphamide and cyclosporine, and high-dose intravenous immunoglobulin have all been used to control hemophagocytic lymphohistiocytosis (HLH) or autoimmune hemolytic anemia (AIHA) associated with systemic lupus erythematosus (SLE); however, some patients are refractory to treatment. Rituximab has successfully resolved many of the refractory manifestations of SLE. Here, we report a case of HLH and AIHA associated with SLE that was refractory or intolerable to conventional therapy, but was successfully treated with rituximab.
大剂量类固醇、免疫抑制剂如环磷酰胺和环孢素以及大剂量静脉注射免疫球蛋白都曾用于控制与系统性红斑狼疮（SLE）相关的噬血细胞性淋巴组织细胞增生症（HLH）或自身免疫性溶血性贫血（AIHA）；然而，一些患者对治疗无效。利妥昔单抗已成功解决了SLE的许多难治性表现。在此，我们报告一例与SLE相关的HLH和AIHA病例，该病例对传统治疗无效或不耐受，但通过利妥昔单抗成功治愈。
